Navigation Links
Medarex Announces 2007 Fourth Quarter and Year End Financial Results
Date:2/26/2008

ll as risks detailed from time to time in Medarex's public disclosure filings with the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the fiscal year ended December 31, 2006. There can be no assurance that such development efforts will succeed or that developed products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success. Copies of Medarex's public disclosure filings are available from its investor relations department.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.

MEDAREX, INC.

Condensed Consolidated Statements of Operations

(In thousands, except per share data)

Year Ended Three Months Ended

December 31, December 31,

(unaudited)

2007 2006 2007 2006

Contract and license

revenues $35,906 $28,289 $15,135 $6,769

Reimbursement of

developments costs 20,352 20,357 5,362 4,557

Total revenues 56,258 48,646 20,497 11,326

Costs and expenses:

Research and development 198,317 194,512 56,857 52,187

General and administrative 46,925 51,928 11,905 16,801

Acquisition of in-process

technology 6,900 - - -

Operating loss (195,884) (197,794) (48,265) (7,662)

Equity in net loss of

affiliate - (1,037) - -

Interest income, net
'/>"/>

SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. Medarex to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
2. Medarex to Receive Milestone Payment for Submission of Regulatory Applications Requesting Approval of Ustekinumab (CNTO 1275) for Treatment of Psoriasis
3. PharmAthene and Medarex Announce Additional $0.8 Million U.S. Government Appropriation for Continued Development of Anthrax Therapeutic Valortim(TM)
4. Medarex to Present at the JPMorgan Small/Mid Cap Conference
5. Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody
6. Grupo Casa Saba Announces Fourth Quarter 2007 Results
7. Lixte Biotechnology Holdings, Inc. Announces Further Developments Regarding the Anti-Cancer Activity of Its Patent-Pending Proprietary Compounds
8. Reproductive Medicine Associates of Texas Announces Open House in San Antonio
9. WallSt.net (www.WallSt.net) Announces Upcoming Interview With Chairman and CEO of flexSCAN, Inc.
10. Hospira Announces New Contract With HealthTrust Purchasing Group for Infusion Devices, Solutions and Equipment
11. Thomson Healthcare Announces Enhancements to Order Sets Solution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... 27, 2015 Cincinnati Veterans Affairs Women’s Health ... Veterans (CERV) Foundation is proud to host the first annual ... Veterans June 11 at the Freedom Center from 6 p.m. ... be the emcee. , This event honors and celebrates ... nation. The banquet is free to the first 150 ...
(Date:5/27/2015)... May 27, 2015 Genius Monkey is ... advanced programmatic marketing technology, they have boosted sales for ... on a regional level for seven Utah-based dealers. ... through television and radio media. In 2014 the Utah ... help of Genius Monkey , shifted their marketing ...
(Date:5/27/2015)... CA (PRWEB) May 27, 2015 With ... total communication environment where the message is not only heard ... toy, drawing, or virtually any motivating image. This award-winning and ... to offer. , Now, using InnerVoice Sender app ... can be sent to a learner remotely for no additional ...
(Date:5/27/2015)... May 27, 2015 With a prevalently ... poll conducted during the "ACA - Controlling the Chaos" ... 75% are currently in the process of researching ... were confidently prepared for the reporting mandates. , According ... the webinar, those who are currently vetting ACA reporting ...
(Date:5/27/2015)... SmarterSkin, http://www.smarterskindermatology.com , is taking skin care ... makes it easier for patients to find skin care products ... Sejal Shah is a cosmetic dermatologist based in New York ... test. This revolutionary DNA test uses 16 genetic markers to ... , 1. Firmness and elasticity , 2. Glycation , ...
Breaking Medicine News(10 mins):Health News:Cincinnati VA Women’s Health Clinic Celebrates Women Veterans at Awards Banquet 2Health News:Genius Monkey Boosts Utah Honda Dealers Website Traffic 142% 2Health News:Newly Released: InnerVoice Sender App Ups the Ante in Communication Technology for Autism with Remote Prompting 2Health News:Newly Released: InnerVoice Sender App Ups the Ante in Communication Technology for Autism with Remote Prompting 3Health News:Newly Released: InnerVoice Sender App Ups the Ante in Communication Technology for Autism with Remote Prompting 4Health News:Employers are On Track for ACA Reporting According to Businessolver Poll 2Health News:SmarterSkin Dermatology is Now Offering Skin DNA Analysis 2
... with language problems might have a lot in common with ... Impairment (SLI) // and they feel that these findings could ... best treatments for individual components of the condition. ,Researchers ... key language center in the brain -- in autistic boys ...
... your child at bedtime would be a pitch-black room as ... risk for leukemia.// ,In the past, research has ... for breast cancer, further supporting the theory that light at ... determined that light at night is found to disrupt the ...
... loss may also help prevent prostate cancer from spreading. A ... spread of cancer to the bone and reduce the risk ... bone loss. ,Estimates show prostate cancer spreads to the ... 311 men who were being given hormone therapy for bone ...
... worth of data on breast cancer patients , researchers say ... at diagnosis and those who are diagnosed at a younger ... to die from the disease. Black women are also more ... are those whose tumors are negative for the estrogen receptor. ...
... 2 diabetes could benefit from statins to reduce their risk ... benefits of statin therapy to reduce cardiovascular disease in // ... diabetics who are at an increased cardiovascular risk would benefit ... to look at the effectiveness of statin therapy among type ...
... who have implanted heart-assist devices, such as pacemakers ... .// ,Pacemakers and defibrillators are battery-operated implantable ... as arrhythmia. Researchers say doctors have feared that ... up metal components of the device, dislodge it, ...
Cached Medicine News:
(Date:5/27/2015)... -- Actavis plc (NYSE: ACT ) announced today ... and Drug Administration (FDA) as a twice-daily, oral ... with diarrhea (IBS-D). VIBERZI (eluxadoline) has mixed opioid ... a delta receptor antagonist, and a kappa receptor ... "The FDA,s approval of VIBERZI is ...
(Date:5/27/2015)... , May 27, 2015 OpportunityAnalyzer: Sepsis ... Sepsis patients suffer from a series of diverse ... toxins in the blood or tissues, which cause a ... leading to mortality rates near 50% depending on disease ... national healthcare systems of the global marketplace, which for ...
(Date:5/27/2015)... May 27, 2015 The prevalence of cardiovascular ... accelerated aging of population and changes in consumption concept, ... been growing year after year, thereby promoting the development ... in China totaled 454,505 in ... interventional cardiovascular device industry there was worth RMB20.12 billion. ...
Breaking Medicine Technology:Actavis Receives FDA Approval for VIBERZI (eluxadoline) for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D) in Adults 2Actavis Receives FDA Approval for VIBERZI (eluxadoline) for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D) in Adults 3Actavis Receives FDA Approval for VIBERZI (eluxadoline) for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D) in Adults 4Actavis Receives FDA Approval for VIBERZI (eluxadoline) for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D) in Adults 5OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 2OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 3OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 4China Interventional Cardiovascular Device Industry Report, 2014-2017 2China Interventional Cardiovascular Device Industry Report, 2014-2017 3
... Alere Health, LLC announced today that it has ... Health Information Products Certification for Health Information Line. ... a 24/7 nurseline staffed by highly experienced, registered ... decisions by providing immediate clinical support for everyday ...
... BOTHELL, Wash., April 6, 2011 BioLife Solutions, Inc. ... grade biopreservation media products for cells and tissues, today ... ended March 31, 2011. This represents 6% sequential growth ... growth from the first quarter of 2010.   ...
Cached Medicine Technology:Alere Earns NCQA Health Information Products Certification for Health Information Line 2BioLife Solutions Announces Record Quarterly Revenue 2BioLife Solutions Announces Record Quarterly Revenue 3BioLife Solutions Announces Record Quarterly Revenue 4
... macular health. Snellen charts available ... Easy to mount on most ... in a few minutes. Rapid ... Retinal vision testing without refraction ...
Eye Q Lite is ideal for color and red-free imaging used in general clinical and optometric casework such as anterior segmenting and diabetic screening....
The Genesis Camera meets the needs of those with specific requirements that cannot be met by a conventional 'chinrest' type camera....
The quick access to diabetic screening, panoramic images of the retina including peripheral area are available by using easy, semi automatic guidance of peripheral fixation....
Medicine Products: